Antitubercular activity assessment of fluorinated chalcones, 2-aminopyridine-3-carbonitrile and 2-amino-4H-pyran-3-carbonitrile derivatives: In vitro, molecular docking and in-silico drug likeliness studies.

A series of newer previously synthesized fluorinated chalcones and their 2-amino-pyridine-3-carbonitrile and 2-amino-4H-pyran-3-carbonitrile derivatives were screened for their in vitro antitubercular activity and in silico methods. Compound 40 (MIC~ 8 μM) was the most potent among all 60 compounds, whose potency is comparable with broad spectrum antibiotics like ciprofloxacin and streptomycin and three times more potent than pyrazinamide. Additionally, compound 40 was also less selective and hence non-toxic towards the human live cell lines-LO2 in its MTT assay. Compounds 30, 27, 50, 41, 51, and 60 have exhibited streptomycin like activity (MIC~16-18 μM). Fluorinated chalcones, pyridine and pyran derivatives were found to occupy prime position in thymidylate kinase enzymatic pockets in molecular docking studies. The molecule 40 being most potent had shown a binding energy of -9.67 Kcal/mol, while docking against thymidylate kinase, which was compared with its in vitro MIC value (~8 μM). These findings suggest that 2-aminopyridine-3-carbonitrile and 2-amino-4H-pyran-3-carbonitrile derivatives are prospective lead molecules for the development of novel antitubercular drugs.

Introduction

TB is responsible for the death of 1.4 million patients and among them 14.86% (2,08,000) were associated with HIV. Mtb is an agile bacterium which can shift from active to latent stage and vice-versa. Additionally, Tuberculosis (TB) is caused by the bacteria Mycobacterium tuberculosis (Mtb), which has been a global concern since decades and big burden on the healthcare system till today. It is one of the top ten leading causes of death according to the World Health Organization (WHO) 2019 reports and pose multiple resistance from the immunological protection of the host [https://www.who.int/news-room/fact-sheets/detail/the-top-10-causes-of-death]. These typical microbiological features of Mtb exhibit for long term therapy and even multi drug resistance (MDR) to the existing WHO treatment protocols. However, due to improved diagnosis and treatment, the incidence of deaths from tuberculosis has been reduced in recent years. It’s anticipated that 66 million were rescued from the death during the year 2000–2020 [https://www.who.int/news-room/fact-sheets/detail/tuberculosis]. Nevertheless, the increase in the incidence of MDR and extensively drug-resistant (XDR) Mtb variants may complicate and create new challenges to this progress. In recent reports comparison in 2018, the number of patients with MDR or rifampicin-resistant TB (RR-TB) has increased by 10% in 2019. India has been listed in the top countries list for RR-TB [1]. MDR-TB, XDR-TB and RR-TB are posing greater challenges in the current treatment tactics employed. This scenario made scientists to drive and emphasize the significance of new research findings and development of new antitubercular medicines to compliment and supplement the current treatment protocols [2].

Chalcones are open chain flavonoids and have received large attention due to their diverse biological activities and synthetic applications in the preparation of medicinally useful heterocyclic molecules [3, 4]. They possess valuable antimicrobial, anti-inflammatory, antitubercular and anticancer activities [5-9]. Among them, fluorinated chalcones (Fig 1) were reported with excellent antimycobacterial activities [10-12]. Pyridine and pyran are biologically useful heterocycles with excellent therapeutic utility. Both these scaffolds are distributed in many naturally derived compounds like alkaloids, flavonoids, glycosides etc. Pyridine derivatives were reported to possess sundry of activities like anticancer, antitubercular, antiviral, antimicrobial, anti-inflammatory, antihistaminic etc., [13-27] and this ring is also present in a large variety of drugs used for the treatment of different diseases [28]. Pyran derivatives have been reported to exhibit antibacterial, anticancer, antitubercular, antioxidant, and other properties [29-37]. Antitubercular medications such as isoniazid, ethionamide, and prothionamide use the pyridine scaffold, whereas aminoglycoside antitubercular medications such as streptomycin, kanamycin, and amikacin use the reduced version of the pyran ring, tetrahydropyran (Fig 1). In the recent past, different fluorinated chalcones, pyridine and pyran derivatives were identified as potential antitubercular lead compounds [38-40] (Fig 2).

Fig 1

Structures of selected marketed antitubercular drugs containing pyridine and tetrahydropyran scaffolds.

Fig 2

Fluorinated chalcones, pyridine and pyran derivatives with significant antitubercular activity.

Fluorine substituents would change the physicochemical properties of drug-like candidates and drugs, such as increased penetration through biological membranes and metabolic stability, lower clearance, pKa value, better binding characteristics and potency [41-44]. Due to its similar sizes, the pyridine ring is a typical bioisosteric scaffold for benzene, pyrrole, and oxazole. In addition, it is utilized to substitute amines and amides bioisosterically. Basicity, stability, reduced molecular size, and aromatic nature confer superior pharmacokinetic qualities and binding abilities to pyridine, making it suitable for use in the preparation of lead molecules [24, 45]. Pyran scaffold like many other heterocyclic rings, aid bioactive compounds in altering pharmacokinetic and pharmacodynamic properties that make it an important component of many pharmaceuticals [46, 47]. In our previous published studies, we reported the antibacterial and antifungal properties of fluorinated chalcones and their pyridine and pyran derivatives with promising activities [48, 49]. Motivated by the excellent antimicrobial activities, we intended to test the target compounds against Mycobacterium tuberculosis in order to identify potential lead molecules against tuberculosis infections. Hence, herein we report the antitubercular evaluation of fluorinated chalcones and their 2-amino-pyridine-3-carbonitrile and 2-amino-4H-pyran-3-carbonitrile derivatives by standard computational and biological methods.

Materials and methods

In vitro antitubercular study

The antimycobacterial activity of target compounds (1–60) were evaluated against Mycobacterium tuberculosis using MABA. Briefly, sterile deionized water (200 μL) was added to all outer perimeter wells of sterile 96 well plate to minimize evaporation of medium in the test wells during incubation. 100 μL of the Middlebrook 7H9 broth was further added and serial dilution of compounds were made directly on plate. The final drug concentrations obtained were 100 to 0.2 μg/mL. The plates were later covered and sealed with parafilm and incubated at 37°C for five days. After incubation, 25 μL of freshly prepared 1:1 mixture of Alamar Blue reagent and 10% tween 80 was added to the plate and incubated for 24 hrs. A blue color in the well was interpreted as no bacterial growth, and pink color was scored as growth. The MIC was defined as lowest drug concentration which prevented the color change from blue to pink [50, 51]. Additionally, cLogP of all the target compounds has been calculated using SwissADME software.

Molecular docking studies

The molecular docking studies on the crystallographic structure of Thymidylate Kinase (PDB ID: 1G3U) retrieved in protein data bank was performed using AUTODOCK 4.2 version [52]. The AUTODOCK TOOLS were utilized for preparing the protein for docking. The polar hydrogen’s, partial charges and Gastegier charges were added using these tools. The flexible torsion of the ligand was assigned to proteins; the Auto Grid tool was used to implement the auto grid file, different for each protein. The grid parameters were set for each run. The AutoDock was run for binding molecules for molecular docking into the crystallographic structure of 1G3U active site. The cube selected covers the protein only of the binding site. The docking log file for each run was used to generate top three binding affinities of each protein, based on the binding energy of compounds. The saved 3D molecular poses were visualized using Discovery Studio.

MTT assay

The most active antitubercular lead compound 40 was screened for its cytotoxicity by MTT assay against the human normal liver cell lines (LO2) to assess its selectivity and safety using the procedure described as per literature [48].

In silico drug likeliness prediction

SwissADME, a web tool was used to evaluate the properties of the most potent compounds 20, 37, 40, and 60, as well as the marketed antitubercular drugs Ciprofloxacin, Streptomycin, and Pyrazinamide, for their in-silico parameters such as GI absorption, Lipinski rule of five, and CYP2C19 and CYP2D6 inhibition, in order to meet the requirements of the drug-likeliness. (http://www.swissadme.ch/ (accessed on 28 June, 2021)) [53].

Results and discussion

Chemistry

The synthesis and characterization of compounds 1–60 has been published previously [48, 49]. Fig 3 depicts the synthesis of target compounds (1–60).

Fig 3

Scheme 1, Synthesis of fluorinated chalcones (1–20) and their 2-amino-pyridine-3-carbonitrile (21–40) and 2-amino-4H-pyran-3-carbonitrile (41–60) derivatives.

In vitro antitubercular activity

Synthesized compounds (1–60) were evaluated for their antitubercular activity against tubercular strain H37RV (Tables 1–3, refer to S1 File). As reference standards, ciprofloxacin (MIC~9 μM), pyrazinamide (MIC ~25 μM), and streptomycin (MIC~11 μM) were utilized. The synthesized compounds can be classified as trifluoromethyl/trifluoromethoxy containing chalcones (1–20); 2-amino-pyridine-3-carbonitrile (21–40) and 2-amino-4H-pyran-3-carbonitrile (41–60) derivatives. The phenyl ring (R"; Tables 1–3, refer to S1 File) was substituted with electron withdrawing groups at ortho, meta, para or ortho-meta positions (compounds 1–6, 11–16, 21–26, 31–36, 41–46, and 51–56). Various heterocycles such as thiophene, furan, pyrrole, and indole ring systems were considered to examine bioisosteric substitution of the phenyl ring (compounds 7–10, 17–20, 27–30, 37–40, 47–50 and 57–60). In case of trifluoromethyl and trifluoromethoxy chalcone series (1–20), the MICs ranged from 38–189 μM (Table 1, refer to S1 File). In trifluoromethyl substituted chalcone derivatives, substituting Cl (10) in the para position resulted in a MIC of 40 μM, whereas substituting Cl in the meta (2)/ortho-meta (3) position or using nitro group in the ortho (4), meta (5), or para (6) position did not improve antitubercular activity when compared to the reference standards. Compounds 10 and 20 had the best activity among the bioisosteres, with MIC values of 40 and 38 μM, respectively.

In case of trifluoromethyl and trifluoromethoxy substituted 2-amino-pyridine-3-carbonitrile series (21–40), the range of MICs values were obtained from 8–134 μM. Substituting electronegative group (Cl or NO2) at positions ortho or para was found to be favorable for activity (compounds 21, 31, 23, 33, 24, 34). However, the compounds bearing heteroaryl scaffold (27–30, 37–40) were more active than the compounds containing phenyl ring with electronwithdrawing groups. Among them, compound 40 containing indole scaffold was most potent with a better MIC value (8 μM). This compound 40 was found to have activity similar to ciprofloxacin and streptomycin but was 3-fold potent than pyrazinamide.

Wheras the trifluoromethyl and trifluoromethoxy substituted 2-amino-4H-pyran-3-carbonitrile series (41–60) were shown the variation of MIC values (16–161 μM). Substitution of the electro negative group (Cl or NO2) at ortho or para positions was found to be more favorable for activity with best activity observed for compounds 41 and 51 with MIC values 17 μM and 16 μM respectively. The lowest activity was detected for 2-pyrrolyl substituent (49 and 59) with MIC values of 151 μM and 144 μM, whereas the best activity was obtained for compounds 50 and 60 containing indole ring with MIC value of 16 μM among all other bioisosteres 47–50, 57–60. Compounds 50 and 60 were found to have activity greater than pyrazinamide but less than ciprofloxacin and streptomycin respectively. Overall, these results indicated cyanopyridines and cyanopyrans as promising lead molecules for the development of newer antitubercular agents. A summary of the antitubercular activities of synthesized compounds (1–60) is depicted in Fig 4 whereas the structure activity relationships is shown in Fig 5.

Fig 4

Summary of the antitubercular activities of fluorinated chalcones (1–20), 2-amino-pyridine-3-carbonitrile (21–40) and 2-amino-4H-pyran-3-carbonitrile (41–60) derivatives.

Fig 5

Structure activity relationships of fluorinated chalcones (1–20), 2-amino-pyridine-3-carbonitrile (21–40) and 2-amino-4H-pyran-3-carbonitrile (41–60) derivatives.

Understanding the mechanism of action of the antitubercular activity of the newly synthesized compounds, molecular docking studies was carried to predict the binding energy of ligands within the binding site of target proteins (Tables 4–6, refer to S1 File, Fig 6). Compound 40 had shown high binding energy (-9.67 kcal/mol) which was correlated with evaluated MIC value of 8 μM. It was found to be too close to methotrexate -10.0287 kcal/mol. Compound 26 had binding energy of -7.97 kcal/mol which corresponded to a MIC value of 33 μM whereas the binding energies for compounds 50 and 60 were found to be -9.82 and -9.49 kcal/mol. We docked the synthesized compounds in the Isoniazid (INH) active site, considering the previously documented thymidylate kinase (TK) inhibitory action of structurally similar pyridine and pyran antimicrobial drugs, as well as isoniazid [50, 54]. TK protein was retrieved from the protein data bank (PDB ID: 1G3U) to validate and designate the target protein for the antibacterial activity of newly synthesized 2-aminopyridine-3-carbonitrile derivative and 2-amino-4H-pyran-3-carbonitrile derivative. The docking conformation of compound 40 suggests good interactions with the active site residues of this protein. The docking interactions of compound 40 clearly reveals the importance of 6-trifluoromethoxyphenyl-4-heteroaryl cyanopyridines in enhancing the antimycobacterial activity over 6-trifluoromethylphenyl-4-heteroaryl cyanopyridines/pyrans. This compound had shown both hydrophobic and hydrogen bonding interactions. For instance, nitrogen of the pyridine scaffold had shown hydrogen bonding with amino acid ASP9 and the amino group at the 2nd position of pyridine ring had additional hydrogen bonding with the amino acids ASP163, GLU166 and MG:300 which enhanced the binding of this compound. In addition, the indole moiety at position-4 had strong hydrophobic (pi-pi stacking) interactions with the amino acid PHE70. The halogen bonding of the trifluoromethoxy group located on the 4th position of the phenyl ring substituted at the position-6 of pyridine motif with ASP94 had further substantiated the binding and enhanced the activity (Fig 6). The other interactions for compound 40 with the protein active site are depicted in Table 7 (refer to S1 File). Hence, the docking studies are in line with the structure activity relationships of the in vitro antitubercular activity data.

Fig 6

2D and 3D interactions of 40 with PZA active site of 1G3U, which shown hydrogen bond and other interactions.

Cytotoxicity assay

The compound 40 was estimated with an IC50 value of >70 μg/mL against the tested human normal liver cell line (LO2) in its in vitro MTT assay (Table 8, refer to S1 File). This result suggested that compound 40 being most potent has selective activity towards the Mycobacterium tuberculosis H37Rv strain over the human cells. Hence it is a safe analogue to process the molecule further to develop the novel antitubercular agent.

In silico drug likeliness studies

Using the web based Swiss ADME program, some parameters of compounds 20, 37, 40 and 60 were computed along with control standards such as Ciprofloxacin, Streptomycin and Pyrazinamide (Table 9, refer to S1 File). The GI absorption was low for compounds 37 and Streptomycin. Compounds 20, 60, Ciprofloxacin and Streptomycin were found to be P-Glycoprotein (PgP) substrates. No compounds and standards allowed Lipinski violations except Streptomycin. In case of CYP2D6 inhibition, all compounds fared well except for 20. Compounds 37, 40 and 60 were found to be CYP2C19 inhibitors. Among all the compounds, 40 fared better in terms of activity and SWISSADME properties compared to 20, 37 and 60. It was observed that 40 inhibited CYP2C19, but did not inhibit CYP2D6. However, it had a high GI absorption rate, did not function as a PgP substrate, and passed the Lipinski Rule of 5. As a result, compound 40 possesses good drug-like qualities and can be used as a new lead compound for additional in-vivo research.

Conclusions

In this present study, a novel series of chalcones, pyridine-3-carbonitrile, 4H-pyran-3-carbonitrile scaffolds were evaluated for their antitubercular activity using in-vitro and in-silico methods. The antitubercular activities of compounds 27, 30, 40, 41, 50, 51, 60 consisting indole and 2-chlorophenyl moiety were exhibited most potency among all compounds being studied. The docking experiments suggested that these compounds might also inhibit 1G3U, considering as promising drug candidates as novel antitubercular drugs. The highest potent compound 40 was selective active against Mycobacterium tuberculosis H37Rv strain compared to the normal human cells and demonstrated good drug-like qualities in the in silico ADME experiments. Compound 40 can be further examined for in vivo characterization. Future research may be extended and continued in the direction of the synthesis of novel analogues and their toxicity testing.

(DOCX)

Click here for additional data file.

2 Jul 2021

Submitted filename: Rebuttal Letter.docx

Click here for additional data file.

2 Sep 2021

PONE-D-21-21460

Antitubercular activity assessment of fluorinated chalcones, 2‐aminopyridine‐3‐carbonitrile and 2‐amino-4H-pyran‐3‐carbonitrile derivatives: In vitro, molecular docking and in-silico drug likeliness studies

PLOS ONE

Dear Dr. Shaik,

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.

Please submit your revised manuscript by Oct 17 2021 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file.

Please include the following items when submitting your revised manuscript:

A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'.

A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'.

An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter.

If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see:  http://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols . Additionally, PLOS ONE offers an option for publishing peer-reviewed Lab Protocol articles, which describe protocols hosted on protocols.io. Read more information on sharing protocols at  https://plos.org/protocols?utm_medium=editorial-email&utm_source=authorletters&utm_campaign=protocols .

We look forward to receiving your revised manuscript.

Kind regards,

Hanna Landenmark

Associate Editor, PLOS ONE

on behalf of

Pooja Chawla

Academic Editor, PLOS ONE

Journal Requirements:

We suggest you thoroughly copyedit your manuscript for language usage, spelling, and grammar. If you do not know anyone who can help you do this, you may wish to consider employing a professional scientific editing service.

Whilst you may use any professional scientific editing service of your choice, PLOS has partnered with both American Journal Experts (AJE) and Editage to provide discounted services to PLOS authors. Both organizations have experience helping authors meet PLOS guidelines and can provide language editing, translation, manuscript formatting, and figure formatting to ensure your manuscript meets our submission guidelines. To take advantage of our partnership with AJE, visit the AJE website ( http://learn.aje.com/plos/ ) for a 15% discount off AJE services. To take advantage of our partnership with Editage, visit the Editage website (www.editage.com) and enter referral code PLOSEDIT for a 15% discount off Editage services. If the PLOS editorial team finds any language issues in text that either AJE or Editage has edited, the service provider will re-edit the text for free.

Please review your reference list to ensure that it is complete and correct. If you have cited papers that have been retracted, please include the rationale for doing so in the manuscript text, or remove these references and replace them with relevant current references. Any changes to the reference list should be mentioned in the rebuttal letter that accompanies your revised manuscript. If you need to cite a retracted article, indicate the article’s retracted status in the References list and also include a citation and full reference for the retraction notice.

Additional Editor Comments (if provided):

Authors have done good work. Although the synthetic part has already been published, the antitubercular activity was carried out. The work could have been substantiated with enzymatic studies. But in my opinion this much work may be published.

[Note: HTML markup is below. Please do not edit.]

Reviewers' comments:

Reviewer's Responses to Questions